Skybiotech Healthcare Approves Q1 Results; Reports Revenue of ₹0.49 Cr and Net Loss of ₹0.57 Cr
Skybiotech Healthcare Limited approved its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, at its board meeting on August 14, 2026. For the quarter, the company posted a revenue of ₹0.49 crore alongside an operating loss of ₹0.52 crore. Net loss for the period stood at ₹0.57 crore with a basic EPS of -₹2.56. The statutory auditor's limited review report was also taken on record without explicit modifications mentioned in the outcome filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுFormal board approval and release of unaudited financial results for the quarter ended June 30, 2026.
ஏன் இது முக்கியம்Demonstrates continued operating losses (₹0.52 crore) on very modest quarterly sales of ₹0.49 crore relative to a net worth of ₹12 crore.
Quarterly Revenue: ₹0.4931 கோடிQuarterly Net Loss: -₹0.5736 crQuarterly EPS: -₹2.56Meeting Date: 14/08/2026
📅 குறுகிய காலம்Performance reflects ongoing operational challenges with no immediate signs of a revenue ramp-up.
📈 நீண்ட காலம்Limited unless the company achieves scale and turns operating profits positive.
⚠ அபாய எச்சரிக்கைகள்
- Persistent operating and net losses
- Extremely low revenue base
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly updates to see if the company can expand its revenue base and reverse operating losses.
